Laboratory Information Management Systems (LIMS) Reshma Kakkar GAP.
Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7,...
Transcript of Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7,...
![Page 1: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/1.jpg)
Somluck Ninwaranon, MD
Piyamitr Sritara, MD, Sukit Yamwong, M
D t t f C di l F lt f MDepartment of Cardiology, Faculty of Me
Ramathibodi Hospital, Mahidol Universit
D
di iedicine
ty
![Page 2: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/2.jpg)
markers associated with various hophysiology process associated
Neutrophilic
p y gy ph acute myocardial infarction
Neutrophilicactivation
BiBiomarin AM
InflammationInflammation
CRPCRPCRPCRP
Endothelial activationactivation
Chan and Ng BMC Medicine 2010, 8:34
NecrosisNecrosis
Troponin
k AVP i rkers MI
AVP axis activation
Biomechanical stress
Biomechanical stress
sST2sST2
BNPBNP
![Page 3: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/3.jpg)
IL 33IL-33
ILIL--1 1 FamilyFamily
![Page 4: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/4.jpg)
Rahul Kakkarr* and Richard T. Lee:voLuME 7, October2008 ,827
![Page 5: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/5.jpg)
Decoy receptor
Rahul Kakkkar* and Richard T. Lee:voLuME 7, October2008 ,827
![Page 6: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/6.jpg)
Rahul Kakkar* and Richard T. Lee:voLuME 7, Octtober2008 ,827
![Page 7: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/7.jpg)
SERUM LEVELS OF THE INTERLEUKINSERUM LEVELS OF THE INTERLEUKINPREDICT MORTALITY AND C
P 0.009
N 1 RECEPTOR FAMILY MEMBER ST2 N-1 RECEPTOR FAMILY MEMBER ST2 CLINICAL OUTCOME IN AMI
sST2 0.379 sST2 0.379 ng/mL
STEMI 810 patients ; TIMI 14 (362)
ENTIRE-TIMI 23(448)ENTIRE TIMI 23(448)
sST2 0.233 ng/mL
Circulation. 2004;109:2186-2190
![Page 8: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/8.jpg)
SERUM LEVELS OF THE INTERLEUMEMBER ST2 PREDICT MORTALITMEMBER ST2 PREDICT MORTALITAMI
UKIN-1 RECEPTOR FAMILY TY AND CLINICAL OUTCOME IN TY AND CLINICAL OUTCOME IN
Circulation. 2004;109:2186-2190
![Page 9: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/9.jpg)
PRE-DISCHARGE RISK STRATIFICATION IN UNOR ITS NATURAL LIGAND IL-33 WHEN COMPA
Elevated sSTM t litMortality At 3
At 1-year HR
sST2
STEMI
NSELECTED STEMI: IS THERE A ROLE FOR ST2ARED WITH CONTEMPORARY RISK MARKERS?
T2 increased risk HR 9 34 30 day HR 9.34 p 0.001
R 3.15 p 0.001
GRACE -RS
677 patients
Int J Cardiol,2012
![Page 10: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/10.jpg)
SOLUBLE ST2 IS ASSOCIATED WITIN PATIENTS WITH HEART FAILURIN PATIENTS WITH HEART FAILUR
Primary end pointsPrimary end points
Death due to WHF
CORONA study 1,449 pts
TH ADVERSE OUTCOMERE OF ISCHAEMIC AETIOLOGYRE OF ISCHAEMIC AETIOLOGY
All cause death
Hospitalization for WHF
European Journal of Heart Failure (2012) 14, 268–277
![Page 11: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/11.jpg)
Measurement of sST2 early after AMmedium-term LV functional recove
12 wk 24 wkMI assists in the prediction of ry
12 wk 24 wk
P 0 16P 0.16
Time after MI
JACC Vol. 55, No. 3, 2010
Time after MI
![Page 12: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/12.jpg)
Is Is Is staIs staasas
the level of soluble ST2 in the level of soluble ST2 in the level of soluble ST2 in able high risk CV patients
i ti ith MACE ?
the level of soluble ST2 in able high risk CV patients
i ti ith MACE ?sociation with MACE ?sociation with MACE ?
![Page 13: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/13.jpg)
Finding associatioFinding associatiocardiovascular ou
Describe sST2 in patients.
on between sST2 & on between sST2 & utcomes.
stable high risk CV g
![Page 14: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/14.jpg)
Inclusion
Age>45 years
Coronary artery diseasey y
Risk ≥ 3 in 7 HTDiabetesDLPCKDSmokingMale age > 55 years female Male age > 55 years, female age > 65 yearsFamily history of premature artherosclerosis
Exclusion
Refuse to inform & consentStudied in others double blind clinical controlled trial . trial . Large aortic dissection that be planned to surgeryLife expectancy < 3 yearsUnderlying disease;
th h t id asthma, rheumatoid arthritis, sepsis
![Page 15: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/15.jpg)
High cardiovascuN= 341 p
341 patients frThai medical sc
(Ramathibodi Chiang(Ramathibodi, Chiang
• Inform consent after doctor exp• Blood sample for sST2 • Cardiovascular history as in pr
SubstudySubstudyCORE
ular risk patients patients
rom 3 sites in chool hospitals
gmai and Srinagarind)gmai and Srinagarind)
plain the study protocol
rotocol at 0, 6 & 12 months
![Page 16: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/16.jpg)
ResultsResults Sub studyCORE
341(100)
ResultsResults
Coronary ydisease
288(84)
MI Non-MI
239(70) 49(14)
PCI189(55)
P13
Non-PCI50(15)
y
CV riskCV risk
53(16)
PCI3(4)
Non-PCI36(11)
![Page 17: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/17.jpg)
Baseline characteristic
Age, year ( mean±SD)
Sex ; Male
Body weight, kg (mean±SD)
Height, cm (mean±SD)
Waist circumference, cm(mean±SD)
Hypertension
Diabetes
Chronic kidney disease
Renal replacement therapy
Kidney transplantation
Dyslipidemia
Smoking
Male elder 65 year, female elder 55 year
Family history of premature CAD
N=341(%)
65 ± 10
206 (59)
63 ± 13
159 ± 8
86 ± 12
241 (71)
145 (43)
60 (18)
4 (1)
1 (0.3)
230 (67)
25 (7)
246 (72)
24 (7)
![Page 18: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/18.jpg)
Baseline characteristic
High risk CV without CAD
Chronic stable angina
Myocardial infarction
Unstable angina
Stroke
Transient ischemic attack
Aortic dissection
Peripheral arterial diseasePeripheral arterial disease
Percutaneous coronary artery interventio
Coronary artery bypassCoronary artery bypass
N=341 (%)
53 (16)
44 (13)
239 (70)
17 (5)
19 (5)
3 (0.9)
3 (0.9)
5 (1)5 (1)
on 202 (59)
15 (4)15 (4)
![Page 19: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/19.jpg)
MedicationAntiplatelet
ASA
Clopidogrel
Ticargrelor
Warfarin
Cilostasol
Antihypertensive Beta-blocker
ACEI
ARBARB
Ca-blocker
NitrateNitrate
diuretic
N=341 (%)( )325 (95)
301(88)
190(56)
1(0.3)
20(6)
3(1)
N=341(%)282(83)
135(40)
105(31)105(31)
120(35)
144(42)144(42)
85(25)
![Page 20: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/20.jpg)
Medication
Anti-lipid agentAnti lipid agent
Statin
FibrateFibrate
Niacin
Ezetimibe
MedicationMedicationDiabetic agent
I liInsulin
Sulfonylurea
Biguanide
Thiazolidinedione
DPP4I
N=341(%)
328(96)328(96)
328(96)
13(4)13(4)
4(1)
20(6)
N=341(%)N=341(%)123(36)
21(6)21(6)
70(21)
92(27)
7(2)
14(4)
![Page 21: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/21.jpg)
MediaMediaMean
sST2
an 25.2(20.4-33.5) ng/mlan 25.2(20.4 33.5) ng/ml 28.7±12.6 ng/ml
EGAT di 18 39(14 7 22 9) / lEGATs : median 18.39(14.7-22.9) ng/ml
2 level
![Page 22: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/22.jpg)
me
me
sST2 level (
sST2 (Non MI)edian 28.0 (22.8-4.6)ng/ml
sST2 (Post MI)sST2 (Post MI)edian 24.3 (19.2-32.8)ng/ml
P value 0 009P value 0.009
ng/ml)
![Page 23: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/23.jpg)
m
m
sST2 le
sST2 (Non PCI)median 27.6(22.8-34.2)ng/ml( ) g
ST2 ( PCI)sST2 ( PCI)median 22.9 (19.0-32.5)ng/ml
P value 0 008P value 0.008
evel ( ng/ml)
![Page 24: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/24.jpg)
ResultsResultsSub study
CORE
ResultsResults
C Coronary disease=288 C
MI=239 Non-MI=4MI=239 Non-MI=4
PCI=189 PCNon-PCI=50
y
CV risk=53
99
CI=13 Non-PCI=36
![Page 25: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/25.jpg)
DMDM(N=147)
sST2 median 26 6(14 6)sST2 median (interquatile)
26.6(14.6)
HT(N=245)( )
sST2 median (interquatile)
26.7(12.9)(interquatile)
CKDCKD(N=62)
sST2 median 30 2(14 5)sST2 median (interquatile)
30.2(14.5)
Non DM P valueNon-DM(N=204)
P-value
24 3(13 7) 0 01224.3(13.7) 0.012
Non-HT(N=106)
P-value( )
21.9(11.4) 0.000
Non CKD P valueNon-CKD(N=289)
P-value
24 7(13 0) 0 00124.7(13.0) 0.001
![Page 26: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/26.jpg)
DLPDLP(N=236)
sST2 median 27 1(13 0)sST2 median (interquatile)
27.1(13.0)
Smoking(N=27)( )
sST2 median (interquatile)
23.5(9.8)(interquatile)
Elderlyy(N=254)
sST2 median 25.9(13.3)(interquatile)
( )
Non DLP P valueNon-DLP(N=115)
P-value
22 5(12 9) 0 00022.5(12.9) 0.000
Non-smoking(N=324)
P-value( )
25.2(13.0) 0.060
Non-elderly P-valuey(N=97)
23.0(12.3) 0.049( )
![Page 27: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/27.jpg)
Male (N=206)Male (N 206)
sST2 median 25.7(12.5)(interquatile)
( )
female (N=145) P-valuefemale (N 145) P value
24.2(15) 0.045( )
![Page 28: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/28.jpg)
sST2 level in Post MI &sST2 level in Post MI &
sST2 level Composite ouNegative
N(%)
Low sST2 < 35 ng/ml 249(92.2
High sST2 ≥ 35 ng/ml 62(87.3High sST2 ≥ 35 ng/ml 62(87.3
Total N(%) 311(91.2
P-value 0 195 P value 0.195 ,
Cut point of sST2
& composite outcomes& composite outcomes
utcome Composite outcome Totale Positive
N(%)
2) 21(7.8) 270(79.2)
3) 9(12.7) 71(20.8)3) 9(12.7) 71(20.8)
2) 30(8.8) 341(100)
Pearson’s R Odd ratio Pearson s R
; 3rd Quartile 1.73
![Page 29: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/29.jpg)
![Page 30: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/30.jpg)
Univariation of sST2 level
HR
N b i kNumber at risksST2 < 35 ng/mlsST2 >= 35 ng/ml
sST2 < 35n
l and composite events
R 1.63 (0.59-2.92) P 0.59
ng/ml sST2 >= 35ng/ml
![Page 31: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/31.jpg)
CONCLCONCLIn stable high risk patients hanormal population(EGAT cohp p (
Median sST2 25 2 ng/ml and Median sST2 25.2 ng/ml and
sST2 in male sex, T2DM, HTN,with higher sST2 level.
LUSIONLUSIONave higher sST2 level more than hort) )
18 39 ng/ml respecti el18.39 ng/ml respectively.
CKD and DLP were associated
![Page 32: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/32.jpg)
CONCLCONCLsST2 in post myocardial infarcPCI have lower sST2 than non
High sST2 le el ≥ 35 ng/ml trHigh sST2 level ≥ 35 ng/ml trcomposite cardiovascular outpatients patients.
LUSIONLUSIONction patients who underwent
n-PCI group.g p
rend to predict higher rend to predict higher tcomes in stable high risk
![Page 33: Somluck Ninwaranon, MD Piyamitr Sritara, MD ...Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 Rahul Kakkar* and Richard T. Lee:voLuME 7, October2008 ,827 SERUM LEVELS](https://reader034.fdocuments.net/reader034/viewer/2022043015/5f37c7f0201f56288b514884/html5/thumbnails/33.jpg)
CLINICAL APPLICATION
sST2 ma be the s rrogate osST2 may be the surrogate ophysician use it for follow up atreatments or new interventiontreatments or new intervention
o tcome for MACE if the outcome for MACE if the after optimal medical n in stable high risk patientsn in stable high risk patients.